GLP-1 Microdosing

Taking less than the label dose of a GLP-1 receptor agonist (semaglutide, tirzepatide) as the goal, rather than as a step in titration. Distinct from two routine practices: starting low and stepping up to manage side-effects, and stepping down rather than stopping abruptly. Microdosing proper is done to cut cost, to avoid side-effects, or to hold weight after a loss on a smaller maintenance dose.

Research notes, not advice. The single source so far is reportage; no trial of sub-label dosing is on record in this vault.

Scale of the practice (2026)

• About one in seven GLP-1 users has microdosed (one estimate, unnamed).
• Up to 55% of microdosers do so without medical supervision (one small survey, unnamed).
• In America it is a product line: Noom, Hims & Hers, and many medical spas offer it; others self-administer at home by syringe withdrawal (contamination risk) or click-counting on pens (error-prone), both of which can push a pen past its 30–60 day shelf life.

State of the evidence

Question	What exists
Does a sub-label dose cause or maintain weight loss?	Anecdote; clinician reports of "super responders"; one April 2026 paper showing gene-dependent response variation
Do the non-weight benefits (cardiovascular, kidney, sleep apnoea) carry over?	No evidence: the trials establishing them used full doses
Will a trial be run?	Unlikely soon: manufacturers have no incentive to fund a study showing less of their product works
Guidance	American Association of Clinical Endocrinology: stick to FDA-approved dosing

The Economist's own framing: "one of the biggest off-label medical experiments ever", resolvable only by trials "the world is far from" running.

Why it matters for the wider GLP-1 story

• It is the demand-side consequence of price: the same direct-to-consumer channels Eli Lilly built (LillyDirect, >half of new patients online) sit next to a grey market of dose-stretching. See Eli Lilly Is Reinventing the Pharma Business (Economist).
• It cuts against the prevention-platform thesis on GLP-1s: if the cardiovascular and renal benefits need full doses, a population on self-selected low doses gets the weight effect (maybe) without the prevention effect (unknown).
• The alternative drug-free route to metabolic improvement, structured diet plus exercise, has a randomised result behind it: see Type 2 Diabetes Remission.

Open questions

• Any randomised comparison of maintenance at sub-label vs label dose after goal weight is reached.
• Whether the April 2026 pharmacogenomic paper's response variation translates into a dosing rule.
• Real prevalence outside America.

Sources

• Should You Microdose GLP-1 Drugs for Weight Loss (Economist) — 2026-07-25, Science & technology